ChemoCentryx Inc. on Monday set a target range of $14 to $16 for its initial public offering.
The target at the top of the range would bring in $64 million, slightly less than the $69 million the Mountain View biopharmaceutical company filed for back in October.
ChemoCentryx, focused on the treatment of autoimmune diseases, inflammatory disorders and cancer, said it plans to offer 4 million shares. At the mid-point of the proposed range, its market value would be $555 million.
No comments:
Post a Comment